trending Market Intelligence /marketintelligence/en/news-insights/trending/iiuejdl1xzcihdsbu0z8jw2 content esgSubNav
In This List

Bellerophon Therapeutics appoints director

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

Blog

Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback

Blog

Infographic: The Big Picture 2023 Issuer & Investor Relations Outlook


Bellerophon Therapeutics appoints director

Bellerophon Therapeutics Inc. elected Matthew Bennett to its board, filling the vacancy left as a result of Adam Weinstein's resignation.

Bennett is the managing director of New Mountain Capital LLC, a private equity firm, which can nominate a member to the Bellerophon board.

Bennett will serve as a class I director until the end of his term in 2021.

Warren, N.J.-based Bellerophon Therapeutics is developing treatments for heart and lung diseases.